Price Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Price Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-8,446	Closed	-$709K	–	167
2018 Q2	$709K	Buy	+8,446	New	+$618K	0.35%	91

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Price Capital Management's ICPT Position: Q3 2018 in Review

Price Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 8,446 shares — an estimated $709K sold.

Price Capital Management first reported a position in ICPT in Q2 2018 and held it in 1 quarter. The position peaked at $709K in Q2 2018. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

Price Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Price Capital Management sold 8,446 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $709K.
Price Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
Price Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $709K in Q2 2018.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on Price Capital Management's 13F filing for Q3 2018, filed 29 Oct 2018.